Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q1 2025 · 10-Q
Revenue$68.61K$68.61K−95.5% vs Q1 2024 Net Income-$3.65M-$3.65MN/M vs Q1 2024 EPS Diluted-$1.97-$1.97N/M vs Q1 2024 Gross Profit$25,544−84.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flow-$808,046N/M Margins · derivedGross margin37.2%+26.6 pt vs Q1 2024
Operating margin-2417.1%−2206.2 pt vs Q1 2024
Net margin-5320.9%−5017.7 pt vs Q1 2024
ended Mar 31, 2025 · filed Jul 11, 2025 · 102 d after period end